A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
Clinical trial NCT05197192 · RECRUITING
Trial details
- NCT number
- NCT05197192
- Sponsor
- German CLL Study Group
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-19
- Primary completion
- 2028-05-01
- Enrollment
- 202
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.